On October 19, 2026, guidance that would facilitate access to compounded, unapproved peptides reached OMB, and some FDA career staff threatened to resign over it. Kennedy has since put out a plan letting compounding pharmacies and telehealth companies sell six unapproved peptides without FDA review. The guidance remains under review, and the debate touches the agency's broader compounded-drug authority.